Lucid Diligence Brief: Mirador Therapeutics $250 million Series B in immuno-fibrotic disease space
Lucid Diligence Brief: Mirador Therapeutics $250 million Series B in…
Lucid Diligence Brief: Amgen acquires Dark Blue Therapeutics
Lucid Diligence Brief: Amgen acquires Dark Blue Therapeutics Professional…
Cardiovascular 2025 Review: From late rescue to earlier, smarter intervention
In 2025, cardiovascular medicine pivoted decisively toward earlier…
Rare Disease 2025 Review: From Orphan Innovation to a System-Level Stress Test
In 2025, rare disease innovation accelerated faster than the systems designed…
Immunology 2025 Review: From Mechanism Proliferation to Platform Discipline
In 2025, immunology moved from breadth to discipline: sharper focus on…
Endocrinology 2025 Review: Outcomes, Access, and Earlier Intervention
In 2025, endocrinology moved decisively toward outcomes that change long-term…
Hematology 2025 Review: Deeper Responses, Faster Translation, and the Push to Scale
The throughline of 2025 was not a single modality—it was the convergence of…
Respiratory 2025 Review: From Symptom Control to Disease Modification
In 2025, respiratory medicine crossed a threshold: biologics entered COPD at…
Neuroscience 2025 Review: Disease Modification Meets Deliverability
The defining idea of 2025 was that CNS innovation became an execution…
Women’s Health 2025 Review: From Fragmented Care to Scaled Platforms
In 2025, women’s health moved decisively from niche innovation toward scaled…
Endocrinology Weekly Update - October 7th 2025
Endocrinology Update: Isturisa dosing model, YAP–T1D link, Mounjaro expansion…
Public Health Weekly News - October 3rd 2025
Public Health Update: Asthma Therapy, Autism Genetics, ALS Pathways, Cancer in…